Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Surface Antigen and Hepatitis C Antibody in Bir Hospital Based Population, Kathmandu, nepal.

Roka K Roka Bista P,

Abstract


Introduction: The global public health burden caused by human immunodeficiency virus, hepatitis B and hepatitis C virus are inflicting serious problems as it has economic and social implications in today’s world. The present study was conducted in Bir hospital in-patient and out-patient departments, to assess the seroprevalence of viral hepatitis B, hepatitis C, human immunodeficiency virus and co-infection of either of these viruses with this retrovirus.

Methods: This was a retrospective study and data were collected of the OPD and IPD patients of Bir hospital, who underwent screening for HbsAg, anti-HCV and anti-HIV antibody and were registered in the laboratory register records of three years duration. HIV antibody detection was performed after pretest counseling and informed consent of the patient. Reactive results of HIV antibody testing were disclosed only after posttest counseling.

Results: The total of 18,427 serum samples were tested and screened for the presence of HBsAg, hepatitis C antibodies and HIV antibody from 2011 to 2013. In three years duration, the total prevalence of hepatitis B was 5.98%, hepatitis C was 1.57% and HIV was 0.89%. In the year 2011, the total seroprevalence of anti-HIV antibody was 0.89%; male 0.67% and female 0.21%. The seroprevalence for HbsAg was found to be 6.5%; male 4.9% and female 1.51%. The seroprevalence for anti-HIV antibody was 2.15%; male 1.84% and female 0.30%. In the year 2012, the total seroprevalence for anti-HIV antibody was 0.9%, male 0.75% and female 0.16%. The seroprevalence for HbsAg was 5.47%; male and female 3.98% and 1.48% respectively. The seroprevalence for anti-HCV was 1.40%, male and female constituted 1.40% and 0.15% respectively. In the year 2013, the total seroprevalence for anti-HIV antibody was 0.87%; male 0.68% and female 0.19%. The seroprevalence was 5.9% for HbsAg, of which male comprised 4.4% and female 1.48%. The seroprevalence for anti-HCV was 1.42% and male and female 1.26 %and 0.15% respectively. In the year 2011, the total no. of cases which had co-infection with HIV and HCV were 9 (0.2%) and all were males. The total no. of cases with co-infection of HBS and HCV were 4 (0.71%), all cases were males. The total no. of cases with co-infection of HIV and HBV were none. In the year 2012, the total no. of cases with co-infection of HIV and HCV were six and constituted 0.10%. All cases were male. The co-infection of HIV and HBV were observed in two cases and constituted 0.03%. Male and female comprised each cases. There was not a single case having co-infection with HBV and HCV in the year 2012. In the year 2013, the total no. of case that had co-infection HIV and HCV were 14 (0.23%), male and female constituted 11 and 3 respectively.

Conclusion: The seroprevalence of HBV, HCV and HIV were more prevalent in patients of third to fifth decades. This has necessitated that we focus our efforts towards primary prevention, behavior change modification, vaccine development and newer approaches for secondary and tertiary prevention to reduce the burden of chronicity and to improve survival for those who already have infections with these agents.

Full Text:

View Pdf